CapsoVision has filed to go public, with plans to raise up to $30 million to support the development of its swallowable ...

Biotech bank balances were again in focus Monday morning, with Tango Therapeutics cutting preclinical work to stretch its ...

Lexeo Therapeutics laid off 15% of its staff last month as part of a wider plan to siphon $20 million from its wider pipeline ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of ...

Dynavax’s battle with activist investor Deep Track Capital over the biopharma’s direction has heated up again as the ...

The FDA has approved its first at-home collection kit that allows women to screen themselves for human papillomavirus (HPV) ...

The National Institutes of Health (NIH) has laid off 250 more employees, with this round of cuts hitting 50 workers at the ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

In the wake of the high-profile departure of Peter Marks, M.D., Ph.D., the FDA has a new leader for its Center for Biologics ...

Vor Bio is the latest cell therapy company to reach the end of the road. | Vor Bio is the latest cell therapy company to ...

Sanofi has scrapped its collaboration with IGM Biosciences, eliminating the biotech’s l | Sanofi has scrapped its ...

RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after ...